A major trial looking at type 2 diabetes and weight loss drugs to protect memory
A major new trial will investigate whether combining GLP-1 drugs currently used for type 2 diabetes and weight loss with lifestyle changes could help protect memory and thinking in older people at risk of cognitive decline.
Could combining lifestyle changes with GLP-1 drugs protect memory and thinking?
A growing body of research demonstrates that modifiable lifestyle factors - including physical activity, nutrition, cardiovascular health, sleep, and social engagement - play a critical role in brain health and dementia risk.
At the same time, emerging evidence from large real-world healthcare datasets suggests that GLP‑1 receptor agonists may reduce dementia risk.
The PROTECT-Cog Study (Prevention of Risk fOr cogniTive dEcline through Combined Therapy) is a first-of-its-kind global clinical trial designed to evaluate whether combining a proven lifestyle intervention with a metabolism-targeting drug can further reduce the risk of cognitive decline, mild cognitive impairment (MCI), and dementia in at-risk older adults.
The dementia trial aims and launch plans
Dr Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society, said:
With around one million people living with dementia in the UK, finding effective ways to reduce our risk is one of the biggest challenges facing dementia research.
'Research part-funded by Alzheimer’s Society established that factors such as physical inactivity, high blood pressure, diabetes and social isolation can affect our risk of developing dementia.
'PROTECT-Cog is one to watch as a new, large-scale study testing whether taking GLP-1 drugs, currently used for type 2 diabetes and weight loss, alongside healthy lifestyle changes could offer additional protection for our memory and thinking as we age.
'However, it’s important not to get ahead of the evidence. The trial has not yet started, and GLP-1 drugs have not been proven to prevent dementia.
Previous studies suggesting people taking these medicines may have a lower dementia risk but cannot tell us whether the drugs themselves caused that reduction.
'The study will also primarily look at changes in memory and thinking, rather than whether people go on to develop dementia, so any positive results would need careful interpretation.
'We look forward to seeing the results of this trial but until we have robust results, nobody should seek GLP-1 drugs specifically to reduce their dementia risk.'
Further information was shared at the Clinical Trials on Alzheimer’s Disease conference (CTAD) about the trial’s aims and launch plans.
Take part in dementia research
Research is only possible thanks to the people who participate. If you would like to get involved in dementia research, we can support you.